Dermatitis

In honor of World Atopic Eczema Day, Almirall announced the launch of its atopic dermatitis awareness campaign, “Moving aheAD,” according to a company press release.

Arcutis Biotherapeutics has submitted a supplemental new drug application to the FDA for roflumilast cream 0.15% for mild to moderate atopic dermatitis treatment in adults and children aged 6 years and older, according to a press release.

Arcutis Biotherapeutics announced interim results of its phase 3, long-term extension trial of roflumilast cream 0.15% for the treatment of atopic dermatitis in adults and children aged 6 years and older, according to a press release.

Children and adults with atopic dermatitis are at an increased risk for inflammatory bowel disease, ulcerative colitis and Chron’s disease, according to a study.

Children and adolescents with atopic dermatitis treated with long-term dupilumab showed positive results and acceptable safety, according to a meta-analysis of multiple studies.

The POCN has launched its Atopic Dermatitis Center of Excellence, a free online resource center for nurse practitioners and physician associates working in the atopic dermatitis field, according to a press release.

Greater atopic dermatitis severity correlated with greater disease burden in children and adolescents in Japan, according to a study.

Dupilumab significantly improved sleep quality, reducing the number of times patients with atopic dermatitis woke up in the middle of the night with pain and itchiness, according to a study.

Arcutis Biotherapeutics and Hangzhou Zhongmei Huadong Pharmaceutical Co. have entered into a strategic collaboration and licensing agreement to develop and commercialize Zoryve in China and Southeast Asia, according to a press release.

Alphyn Biologics presented interim data from the second cohort of its phase 2a clinical trial program of AB-101a for the treatment of atopic dermatitis, according to a presentation at the Society for Pediatric Dermatology annual meeting.